Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia.
Ravindranathan
M
M
Klementich
F J
FJ
Jones
D V
DV
D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy; D000368:Aged; D000753:Anemia, Refractory / Q000139:chemically induced*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004347:Drug Interactions; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000502:physiology; D000077156:Gefitinib; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D008297:Male; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D000093542:Gemcitabine
D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D003841:Deoxycytidine; D016190:Carboplatin; C512478:EGFR protein, human; D066246:ErbB Receptors; D002945:Cisplatin; D000077156:Gefitinib; D000093542:Gemcitabine